Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Ardea Biosciences, Inc.
Age
18–65
Sex
MALE
Healthy volunteers
Accepted
You may be eligible if
Subject is able to understand the study procedures and the risks involved, and is willing to provide written informed consent before the first study-related activity.
Subject has a body weight ≥ 50 kg (110 lbs.) and a body mass index ≥ 18 and ≤ 40 kg/m2.
Subject has a Screening serum urate level of 4 to 7 mg/dL.
Subject is free of any clinically significant disease or medical condition, per the Investigator's judgment.
You may not be if
Subject has a history or suspicion of kidney stones.
Subject has undergone major surgery within 3 months prior to Screening.
Subject donated blood or experienced significant blood loss within 12 weeks prior to Day 1 or gave a plasma donation within 4 weeks prior to Day 1.
Subject has clinically unacceptable physical examination, per the Investigator's judgment.
Subject has clinically relevant abnormalities in blood pressure, heart rate, or body temperature, per the Investigator's judgment.
Subject has Screening clinical safety laboratory parameters (serum chemistry \[other than serum creatinine and serum urate\], hematology, coagulation or urinalysis) that are outside the normal limits and are considered clinically significant by the Investigator.
Subject has a serum creatinine value above the upper limit of normal at the Screening visit.
Subject has clinically relevant abnormalities in 12-lead electrocardiogram, per the Investigator's judgment.
Subject has a history of cardiac abnormalities
Subject cannot swallow multiple tablets or capsules.
Subject has received any strong or moderate enzyme-inducing drug or product within 2 months prior to Day 1.
Clareo Health | RDEA3170 Tablet and Capsule Bioavailability Study
